Skip to content

Ketamine for depression: all studies

Page 70 of 154: studies 691 to 700 of 1,534, newest first. Back to the ketamine for depression overview

Research

Is the antidepressant effect of ketamine separate from its psychotomimetic effect? A review of rodent models.

Neuropharmacology November 1, 2024 M C Acero-Castillo, M B M Correia, F V Caixeta et al. 7 citations

Ketamine is an NMDA (N-methyl-d-aspartate) glutamate receptor antagonist, which has a myriad of dose-dependent pharmacological and behavioral effects, including anesthetic, sedative, amnestic, analgesic, and anti-inflammatory properties. Intriguingly, ketamine at subanesthetic doses displays a relevant profile both in mimicking symptoms of schizophrenia and also as the first fast-acting...

Rethinking the role of TRKB in the action of antidepressants and psychedelics.

Trends in Neurosciences November 1, 2024 Cecilia Anna Brunello, Cecilia Cannarozzo, Eero Castrén 29 citations

Antidepressant drugs promote neuronal plasticity, and activation of brain-derived neurotrophic factor (BDNF) signaling through its receptor neuronal receptor tyrosine kinase 2 (NTRK2 or TRKB) is among the critical steps in this process. These mechanisms are shared by typical slow-acting antidepressants, fast-acting ketamine, and psychedelic compounds, although the cellular targets of each drug...

The effect of a subclinical dose of esketamine on depression and pain after cesarean section: A prospective, randomized, double-blinded controlled trial.

Medicine November 1, 2024 Xiangqian Wan, Ming Li, Xiantao Li et al. 8 citations

The aim of this randomized, double-blind placebo-controlled clinical trial was to study the effects of subclinical doses of esketamine on postpartum depression and pain following elective cesarean sections. This randomized, double-blind placebo-controlled trial included 150 pregnant women undergoing elective cesarean sections. After umbilical cord clamping, participants received either...

DOI: 10.1097/MD.0000000000040295 (opens in new tab) Full text (opens in new tab) Pain management Obstetrics Anesthesia Cesarean section +1

Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies.

The International Journal of Neuropsychopharmacology November 1, 2024 Randall L. Morrison, Jaskaran Singh, Ella Daly et al. 9 citations

While esketamine is effective in treatment-resistant depression (TRD), detailed information about the effect of esketamine on cognition is relatively scarce. This analysis assessed the effect of short-term (3 double-blind [DB] studies: DB1, DB2, and DB4) or long-term maintenance treatment (DB3) with esketamine nasal spray (ESK) compared with a placebo (PBO) combined with active-comparator, on...

DOI: 10.1093/ijnp/pyae046 (opens in new tab) Full text (opens in new tab) Esketamine Cogstate battery test Randomized controlled trials Depression treatment +7

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): commentary, Joks et al.

The British journal of psychiatry : the journal of mental science November 1, 2024 Gero Joks, Steve Su, Jarrad King

Regarding the article, 'Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial', we commend Loo et al for undertaking the Ketamine for Adult Depression Study (KADS). In the interest of ensuring that accurate and balanced information is presented to healthcare...

DOI: 10.1192/bjp.2024.79 (opens in new tab) Full text (opens in new tab) Major depressive disorder Depression/mental health/mental illness Ketamine/esketamine/psychedelics Treatment-resistant depression/trd/refractory depression

Efficacy of esketamine for perinatal depression: a systematic review and meta-analysis.

CNS Spectrums October 31, 2024 Sabrina Wong, Gia Han Le, Angela T H Kwan et al. 10 citations

Postpartum depression (PPD), now referred to as perinatal depression, is a prevalent and debilitating mood disorder that reduces health-related quality of life (HRQoL) and psychosocial functioning. Esketamine, which is efficacious in adults with treatment-resistant depression and individuals with depression and suicidality, is also analgesic in pain management during childbirth labour. Herein,...

DOI: 10.1017/S1092852924000452 (opens in new tab) Full text (opens in new tab) Spravato Mdd prevention Perinatal depression Postpartum depression ppd +4

Ketamine-induced altered states of consciousness: a systematic review of implications for therapeutic outcomes in psychiatric practices.

European Archives of Psychiatry and Clinical Neuroscience October 28, 2024 Kaike Thiê da Costa Gonçalves, Vagner Deuel O de Tavares, Maria Luiza de Morais Barros et al. 5 citations

This systematic review aims to elucidate the nexus between ketamine's psychoactive properties and its efficacy in treating a broad spectrum of psychiatric disorders. We searched three databases and used citation tracking to include 29 studies. Predominantly, mood disorders, including bipolar disorder (BD) and major depressive disorder (MDD) (MDD + BD: + n = 25 studies), a large part of them...

Ketamine and chronic treatment-resistant depression: real-world practice and after relapse.

BMC Psychiatry October 28, 2024 Sumaya Jobnah, Youssef Latifeh, Dina Al Kabani et al. 2 citations

Chronic treatment-resistant depression (TRD) poses a major challenge for clinicians. Ketamine has shown a rapid but short-lived antidepressant effect in several studies involving TRD patients with different demographic and clinical profiles. Our study aimed to assess the antidepressant effect of serial infusion sessions of ketamine in patients with chronic TRD and evaluate the severity of...

Advancing ketamine in the treatment hierarchy for refractory depression.

The British journal of psychiatry : the journal of mental science October 25, 2024 Kabir Nigam, Franklin King, Fernando Espí Forcén 2 citations

Evidence indicates that ketamine is highly effective, has a lower side effect profile and is better tolerated compared to many augmentation strategies for refractory depression. This, combined with data on psychiatric treatment outcome mediators, suggests that earlier intervention with ketamine could improve outcomes for patients suffering from refractory depression.

DOI: 10.1192/bjp.2024.217 (opens in new tab) Full text (opens in new tab) Antidepressants Depressive disorders General adult psychiatry Psychopharmacology +6

A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists.

Journal of Affective Disorders October 15, 2024 Angela T H Kwan, Joshua D. Rosenblat, Rodrigo B. Mansur et al. 13 citations

Ketamine and esketamine are increasingly prescribed in the treatment of resistant mood disorders and persons at risk of suicide. Ketamine is a drug of misuse with increasing non-therapeutic use in the general population. Herein, our aim was to determine whether ketamine and/or esketamine are disproportionately associated with reports of substance and/or alcohol misuse. Replicating a similar...